Cipher Pharmaceuticals (TSE:CPH) Shares Pass Below 50 Day Moving Average – Should You Sell?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR)’s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$17.86 and traded as low as C$16.57. Cipher Pharmaceuticals shares last traded at C$16.57, with a volume of 22,976 shares.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group set a C$17.00 target price on shares of Cipher Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of C$17.00.

Cipher Pharmaceuticals Stock Up 1.1%

The business’s 50 day moving average is C$17.84 and its 200 day moving average is C$15.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.67 and a current ratio of 1.25. The stock has a market cap of C$423.78 million, a price-to-earnings ratio of 14.03 and a beta of 0.89.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings data on Thursday, May 7th. The company reported C$0.33 EPS for the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. The firm had revenue of C$17.39 million during the quarter. Equities analysts expect that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.